COCP

Cocrystal Pharma, Inc.

Price Chart

Latest Quote

$0.95

-0.01 (-1.03%)

Current Price

Previous Close	$0.96
Open	$0.97
Day High	$0.98
Day Low	$0.95
Volume	7,675

Fetched: 2026-07-17T04:37:57

Stock Information

Shares Outstanding	13.79M
Total Debt	$1.42M
Cash Equivalents	$4.68M
Revenue	$225K
Net Income	$-8.83M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$13.10M
EPS (TTM)	$-0.72
Exchange	NCM

🌐 Visit Website

Recent Price History

Date	Close	Volume
2026-07-17	$0.95	12,100
2026-07-16	$0.95	7,700
2026-07-15	$0.96	32,400
2026-07-14	$0.94	61,500
2026-07-13	$0.96	27,900
2026-07-10	$1.01	10,000
2026-07-09	$1.01	18,400
2026-07-08	$0.98	19,000
2026-07-07	$1.02	29,500
2026-07-06	$1.04	14,600
2026-07-02	$1.04	17,300
2026-07-01	$1.05	35,000
2026-06-30	$1.05	47,600
2026-06-29	$1.03	52,200
2026-06-26	$1.02	67,900
2026-06-25	$1.01	97,200
2026-06-24	$1.05	112,100
2026-06-23	$1.06	132,500
2026-06-22	$1.00	104,400
2026-06-18	$1.00	74,300

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.

📰 Latest News

We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Simply Wall St. • 2026-04-04T12:57:01Z

BC-Most Active Stocks

Associated Press Finance • 2025-09-12T14:30:22Z

Wall Street Set to Open Little Changed Friday Ahead of Consumer Sentiment Report

MT Newswires • 2025-09-12T13:21:29Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$9,019,000	$17,878,000	$21,159,000	$18,137,000
Other Income Expense	$54,000	$-163,000	$2,535,000	$-20,698,000
Net Non Operating Interest Income Expense	$134,000	$537,000	$640,000	$-2,000
Total Other Finance Cost	$-134,000	$-537,000	$-640,000	$2,000
Operating Expense	$9,019,000	$17,878,000	$21,159,000	$18,137,000
General And Administrative Expense	$3,964,000	$5,341,000	$5,990,000	$5,745,000
Interest Expense	-	-	-	$2,000
Interest Expense Non Operating	-	-	-	$2,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Net Interest Income	$134,000	$537,000	$640,000	$-2,000
Normalized Income	$-8,885,000	$-17,341,000	$-20,519,000	$-18,139,000
Net Income From Continuing And Discontinued Operation	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Total Operating Income As Reported	$-9,019,000	$-17,878,000	$-18,559,000	$-38,829,000
Net Income Common Stockholders	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Net Income	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Net Income Including Noncontrolling Interests	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Net Income Continuous Operations	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Pretax Income	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Operating Income	$-9,019,000	$-17,878,000	$-21,159,000	$-18,137,000
Special Income Charges	-	$0	$2,600,000	$-20,692,000
Per Share
Diluted EPS	$-0.78	$-1.72	$-1.87	$-4.77
Basic EPS	$-0.78	$-1.72	$-1.87	$-4.77
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-8,697,000	$-17,269,000	$-23,694,000	$2,949,000
Total Unusual Items	$54,000	$-163,000	$2,535,000	$-20,698,000
Total Unusual Items Excluding Goodwill	$54,000	$-163,000	$2,535,000	$-20,698,000
Reconciled Depreciation	$376,000	$446,000	$-1,388,000	$388,000
EBITDA (Bullshit earnings)	$-8,643,000	$-17,432,000	$-21,159,000	$-17,749,000
EBIT	$-9,019,000	$-17,878,000	$-21,159,000	$-18,137,000
Diluted Average Shares	$11,290,000	$10,174,000	$9,651,000	$8,143,000
Basic Average Shares	$11,290,000	$10,174,000	$9,651,000	$8,143,000
Diluted NI Availto Com Stockholders	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Gain On Sale Of Security	$54,000	$-163,000	$-65,000	$-6,000
Research And Development	$5,055,000	$12,537,000	$15,169,000	$12,392,000
Selling General And Administration	$3,964,000	$5,341,000	$5,990,000	$5,745,000
Other Gand A	$3,964,000	$5,341,000	$5,990,000	$5,745,000
Other Special Charges	-	-	$-2,600,000	$1,600,000
Impairment Of Capital Assets	-	-	$0	$19,092,000

Fetched: 2026-07-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$6,331,000	$9,523,000	$26,384,000	$39,567,000
Total Assets	$9,712,000	$13,456,000	$31,259,000	$40,840,000
Total Non Current Assets	$1,578,000	$1,876,000	$2,168,000	$662,000
Non Current Prepaid Assets	$95,000	$29,000	$46,000	$46,000
Current Assets	$8,134,000	$11,580,000	$29,091,000	$40,178,000
Other Current Assets	$328,000	$430,000	$1,773,000	$2,243,000
Restricted Cash	$75,000	$75,000	$75,000	$75,000
Receivables	$706,000	$1,215,000	$890,000	$716,000
Taxes Receivable	$706,000	$1,215,000	$890,000	$716,000
Cash Cash Equivalents And Short Term Investments	$7,025,000	$9,860,000	$26,353,000	$37,144,000
Cash And Cash Equivalents	$7,025,000	$9,860,000	$26,353,000	$37,144,000
Cash Financial	$7,025,000	$9,860,000	$26,353,000	$37,144,000
Goodwill And Other Intangible Assets	-	-	-	$0
Prepaid Assets	-	-	-	-
Accounts Receivable	-	-	-	-
Debt
Total Debt	$1,505,000	$1,806,000	$1,853,000	$297,000
Long Term Debt And Capital Lease Obligation	$1,171,000	$1,505,000	$1,613,000	$57,000
Current Debt And Capital Lease Obligation	$334,000	$301,000	$240,000	$240,000
Liabilities
Total Liabilities Net Minority Interest	$3,381,000	$3,933,000	$4,875,000	$1,273,000
Total Non Current Liabilities Net Minority Interest	$1,171,000	$1,505,000	$1,613,000	$57,000
Current Liabilities	$2,210,000	$2,428,000	$3,262,000	$1,216,000
Payables And Accrued Expenses	$1,791,000	$2,010,000	$2,913,000	$846,000
Payables	$890,000	$1,542,000	$1,222,000	$614,000
Accounts Payable	$890,000	$1,542,000	$1,222,000	$614,000
Other Current Liabilities	-	-	-	-
Equity
Common Stock Equity	$6,331,000	$9,523,000	$26,384,000	$39,567,000
Total Equity Gross Minority Interest	$6,331,000	$9,523,000	$26,384,000	$39,567,000
Stockholders Equity	$6,331,000	$9,523,000	$26,384,000	$39,567,000
Retained Earnings	$-342,249,000	$-333,418,000	$-315,914,000	$-297,930,000
Other
Ordinary Shares Number	$13,784,065	$10,173,790	$10,173,790	$8,143,000
Share Issued	$13,784,065	$10,173,790	$10,173,790	$8,143,000
Tangible Book Value	$6,331,000	$9,523,000	$26,384,000	$39,567,000
Invested Capital	$6,331,000	$9,523,000	$26,384,000	$39,567,000
Working Capital	$5,924,000	$9,152,000	$25,829,000	$38,962,000
Capital Lease Obligations	$1,505,000	$1,806,000	$1,853,000	$297,000
Total Capitalization	$6,331,000	$9,523,000	$26,384,000	$39,567,000
Additional Paid In Capital	$348,567,000	$342,931,000	$342,288,000	$337,489,000
Capital Stock	$13,000	$10,000	$10,000	$8,000
Common Stock	$13,000	$10,000	$10,000	$8,000
Long Term Capital Lease Obligation	$1,171,000	$1,505,000	$1,613,000	$57,000
Current Capital Lease Obligation	$334,000	$301,000	$240,000	$240,000
Pensionand Other Post Retirement Benefit Plans Current	$85,000	$117,000	$109,000	$130,000
Current Accrued Expenses	$901,000	$468,000	$1,691,000	$232,000
Net PPE	$1,483,000	$1,847,000	$2,122,000	$616,000
Accumulated Depreciation	$-2,001,000	$-1,929,000	$-1,803,000	$-1,614,000
Gross PPE	$3,484,000	$3,776,000	$3,925,000	$2,230,000
Other Properties	$3,329,000	$3,621,000	$3,770,000	$2,099,000
Machinery Furniture Equipment	$155,000	$155,000	$155,000	$131,000
Goodwill	-	-	-	$0

Fetched: 2026-07-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-8,204,000	$-16,493,000	$-14,784,000	$-21,509,000
Operating Activities
Operating Cash Flow	$-8,192,000	$-16,485,000	$-14,666,000	$-21,435,000
Cash Flow From Continuing Operating Activities	$-8,192,000	$-16,485,000	$-14,666,000	$-21,435,000
Operating Gains Losses	-	-	-	$-12,000
Investing Activities
Capital Expenditure	$-12,000	$-8,000	$-118,000	$-74,000
Investing Cash Flow	$-12,000	$-8,000	$-118,000	$-74,000
Cash Flow From Continuing Investing Activities	$-12,000	$-8,000	$-118,000	$-74,000
Financing Activities
Issuance Of Capital Stock	$5,369,000	$0	$4,000,000	$0
Financing Cash Flow	$5,369,000	$0	$3,993,000	$-27,000
Cash Flow From Continuing Financing Activities	$5,369,000	$0	$3,993,000	$-27,000
Net Common Stock Issuance	$5,369,000	$0	$4,000,000	$0
Common Stock Issuance	$5,369,000	$0	$4,000,000	$0
Other
End Cash Position	$7,100,000	$9,935,000	$26,428,000	$37,219,000
Beginning Cash Position	$9,935,000	$26,428,000	$37,219,000	$58,755,000
Changes In Cash	$-2,835,000	$-16,493,000	$-10,791,000	$-21,536,000
Net PPE Purchase And Sale	$-12,000	$-8,000	$-118,000	$-74,000
Purchase Of PPE	$-12,000	$-8,000	$-118,000	$-74,000
Change In Working Capital	$294,000	$140,000	$2,342,000	$-2,712,000
Change In Payables And Accrued Expense	$-251,000	$-895,000	$2,046,000	$-321,000
Change In Prepaid Assets	$36,000	$1,360,000	$470,000	$-1,675,000
Change In Receivables	$509,000	$-325,000	$-174,000	$-716,000
Other Non Cash Items	$-301,000	$-210,000	$1,563,000	$-209,000
Stock Based Compensation	$270,000	$643,000	$801,000	$855,000
Depreciation Amortization Depletion	$376,000	$446,000	$-1,388,000	$388,000
Depreciation And Amortization	$376,000	$446,000	$-1,388,000	$388,000
Depreciation	$376,000	$446,000	$-1,388,000	$388,000
Net Income From Continuing Operations	$-8,831,000	$-17,504,000	$-17,984,000	$-38,837,000
Repayment Of Debt	-	$0	$-7,000	$-27,000
Net Issuance Payments Of Debt	-	$0	$-7,000	$-27,000
Net Long Term Debt Issuance	-	$0	$-7,000	$-27,000
Long Term Debt Payments	-	$0	$-7,000	$-27,000
Asset Impairment Charge	-	-	$0	$19,092,000
Changes In Account Receivables	-	-	-	$0
Gain Loss On Investment Securities	-	-	-	$-12,000
Change In Other Current Assets	-	-	-	-

Fetched: 2026-07-15